Health
STAT+: Peptide market poised to explode with new Hims and Noom launches
Publication: STAT
Author: Sarah Todd and Katie Palmer
Source published: 19/11/2026, 16:59:47 UTC
Briefing created: 19/11/2026, 17:09:22 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/11/2026, 17:06:24 UTC.
Briefings
Two major telehealth companies, Hims and Noom, announced the launch of prescription-only peptide products, marking a potential mainstream shift for synthetic amino acids. These companies hold significant market positions with Hims valued at over $3.5 billion and Noom at $3.7 billion. However, the evidence explicitly states that these compounded peptides are experimental, have not received FDA approval, and lack randomized controlled trials confirming safety or efficacy in humans.
Key points
- Hims and Noom are the two dominant telehealth companies announcing prescription peptide products, with Hims having a market cap of more than $3.5 billion and Noom valued at $3.7 billion.
- The evidence explicitly states that the marketed peptides are experimental, have not received FDA approval, and lack randomized controlled trials showing safety and efficacy in humans.
Context
Peptides are a broad category of short-chain amino acids, initially popular among bodybuilders but now gaining traction for health optimization. While smaller telehealth companies previously offered prescriptions, the announcement from Hims and Noom represents a pivotal moment for the industry.
Limitations
The evidence explicitly states that the marketed peptides are experimental, have not received FDA approval, and lack randomized controlled trials showing safety and efficacy in humans. The evidence does not provide details on specific drug names, dosages, or patient outcomes.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/11/2026, 17:09:22 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeib4zhmbuspyhvptrxraoxbdsy7wfuac3nvvs2hndig2xawstcxeny